Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

21 Apr 2021 07:00

RNS Number : 0754W
Bunzl PLC
21 April 2021
 

21 April 2021

 

BUNZL Q1 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 31 December 2020.

 

Bunzl's diversified and resilient business model has delivered good overall growth against continuing pandemic-related challenges, with Group revenue in the first quarter up 5.4% at actual exchange rates and 10.4% at constant exchange rates. Acquisitions contributed revenue growth of 4.3% at constant exchange rates, while a greater number of trading days than the comparable period in 2020 further benefited revenue growth by 4.7%. Underlying revenue growth at constant exchange rates increased by 1.4%, in line with the Group's expectations. Group adjusted operating margin continued to be supported by demand for certain Covid-19 related products.

 

Within underlying revenue growth of 1.4%, sales of the top 8 Covid-19 related products, which are primarily own brand, contributed 6.4% of growth. This growth more than offset a 5.0% decline in revenue from other product sales. Good underlying revenue performance in North America and Rest of the World was driven by demand for Covid-19 related products, with certain category-specific pricing remaining elevated, and a continuation of the recovery in sales of other products. Continental Europe and UK & Ireland continued to be impacted by the effect of pandemic-related restrictions, particularly on foodservice and non-food retail segments.

 

The Group's guidance remains unchanged. At constant exchange rates, the Group continues to expect robust revenue growth in 2021 compared to the prior year, after excluding larger Covid-19 related orders which contributed approximately £550 million of revenue in 2020. A recovery in sales of other products is expected to be largely offset by a decline in smaller Covid-19 related orders, while recent acquisitions will further contribute to the Group's performance in 2021. After excluding larger Covid-19 related orders, the Group continues to expect good organic revenue growth in the first half of 2021 to be followed by a moderate decline in the second half. Group adjusted operating margin for the year is expected to return to a more historical level.

 

Commenting on today's results, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Now over a year on from the start of the pandemic I continue to thank our colleagues for their exceptional hard work supporting front line heroes and essential businesses through these extraordinary times. As activity starts to resume in some of our markets, it is with pride that I now see our teams increasingly supporting customers to reopen their businesses, many of which have been meaningfully impacted over the course of the pandemic. The resilience of the Bunzl model continues to be demonstrated by our ability to respond to changing customer needs and through our financial performance.

 

Looking ahead we are confident in the strength of our consistent and proven compounding strategy, supported by enhanced hygiene trends, our differentiated offering of sustainable and responsible solutions and acquisition momentum. We have announced three acquisitions in the year to date with the pipeline remaining active and a number of discussions ongoing."

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

David Allchurch

Martin Robinson

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBSGDSCUDDGBG
Date   Source Headline
1st Apr 202211:13 amRNSTotal Voting Rights
17th Mar 20224:15 pmRNSAnnual Financial Report
15th Mar 202211:30 amRNSDirector Declaration
3rd Mar 20225:07 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:12 pmRNSDirector/PDMR Shareholding
2nd Mar 20225:36 pmRNSDirector/PDMR Shareholding
1st Mar 20225:58 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20229:00 amRNSDirector Declaration
28th Feb 20227:00 amRNSAnnual Financial Report
3rd Feb 20224:06 pmRNSDirector/PDMR Shareholding
2nd Feb 20225:30 pmRNSDirectorate Change
1st Feb 202210:58 amRNSTotal Voting Rights
12th Jan 202212:15 pmRNSDirector/PDMR Shareholding
12th Jan 20227:00 amRNSAcquisition
10th Jan 20225:34 pmRNSDirector/PDMR Shareholding
7th Jan 202211:54 amRNSDirector/PDMR Shareholding
4th Jan 20225:56 pmRNSTotal Voting Rights
15th Dec 20217:00 amRNSTrading Statement
10th Dec 20213:18 pmRNSDirector/PDMR Shareholding
8th Dec 20214:30 pmRNSDirector Declaration
8th Dec 20218:00 amRNSAdditional Listing
3rd Dec 20214:27 pmRNSDirector/PDMR Shareholding
1st Dec 20214:50 pmRNSDirector/PDMR Shareholding
1st Dec 202110:20 amRNSTotal Voting Rights
18th Nov 20217:00 amRNSAcquisition
10th Nov 20213:00 pmRNSPublication of Admission Particulars
4th Nov 20215:41 pmRNSDirector/PDMR Shareholding
3rd Nov 202112:35 pmRNSDirector/PDMR Shareholding
3rd Nov 202112:35 pmRNSDirector/PDMR Shareholding
1st Nov 20213:14 pmRNSTotal Voting Rights
1st Nov 20219:00 amRNSBlock listing Interim Review
29th Oct 20211:10 pmRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSTrading Statement
19th Oct 20215:12 pmRNSDirector/PDMR Shareholding
19th Oct 20215:11 pmRNSDirector/PDMR Shareholding
11th Oct 20217:00 amRNSCapital Markets Day
8th Oct 20212:28 pmRNSDirector/PDMR Shareholding
8th Oct 20212:24 pmRNSDirector/PDMR Shareholding
5th Oct 202110:16 amRNSDirector/PDMR Shareholding
1st Oct 202112:36 pmRNSTotal Voting Rights
14th Sep 20217:00 amRNSAcquisition
3rd Sep 202112:30 pmRNSDirector/PDMR Shareholding
1st Sep 20214:00 pmRNSTotal Voting Rights
31st Aug 20214:30 pmRNSDividend Declaration
31st Aug 20217:00 amRNSHalf-year Report
31st Aug 20217:00 amRNSAcquisition
4th Aug 202111:24 amRNSDirector/PDMR Shareholding
2nd Aug 20213:40 pmRNSTotal Voting Rights
14th Jul 20214:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.